Results

1–10 of 22 results for fluocinolone acetonide

Fluocinolone Intravitreal Implant in Patients With Macular Edema Due to Retinal Vein Occlusion
Ashkan M. Abbey, MD, FASRS, FAAO
On Demand Cases, Courses, and Papers
2021
Characteristics and the Need for Supplementation Following 0.19mg Fluocinolone Acetonide (FAc) in Diabetic Macular Edema (DME) Patients
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2021
Diabetic Retinopathy Progression in Anti-VEGF Versus Fluocinolone Acetonide Implant Treated Eyes Who Are Lost to Follow-up
Caesar K. Luo, MD, FASRS
Annual Meeting Talks
2020
Course of Macular Edema Through 36 Months With Fluocinolone Acetonide Intravitreal Insert for Non-infectious Uveitis Affecting the Posterior Segment
Seenu M. Hariprasad, MD
Annual Meeting Talks
2020
Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis following an Injectable Fluocinolone Acetonide Insert
Dilraj S Grewal, MD, FASRS
Annual Meeting Talks
2020
Variability of Retinal Thickness in Diabetic macular edema (DME) Patients Treated with 0.19mg Fluocinolone Acetonide (FAc, ILUVIEN).
Christopher D. Riemann, MD
On Demand Cases, Courses, and Papers
2019
Inflammatory and Infectious Diseases Symposium
Annual Meeting Talks
2020
Diabetic Retinopathy Progression in Anti-VEGF versus Fluocinolone Acetonide Implant Treated Eyes Who are Lost to Follow-up
Caesar K. Luo, MD, FASRS
Updates from the Field
2020
Cumulative recurrences With the Fluocinolone Acetonide Intravitreal Insert for NIPU: 36-Month Results
David Callanan, MD
Annual Meeting Talks
2019
36-Month Outcomes of Injectable Fluocinolone Acetonide Intravitreal Insert on Recurrences of Non-infectious Posterior Segment Uveitis
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2019